Trevi Therapeutics Reports Progress in Chronic Cough Trials

Trevi Therapeutics, a biopharmaceutical company focused on developing treatments for chronic cough and idiopathic pulmonary fibrosis (IPF), recently updated investors on its clinical trials and financial performance during the Second Quarter 2024 Earnings Conference Call. The company reported a net loss of $12.4 million for the quarter but confirmed it has sufficient funding to last into 2026.

Trevi is making progress with multiple clinical trials, with critical data readouts anticipated by the end of this year and in early 2025. The appointment of Dr. Meg Garin to lead the RIVER trial for refractory chronic cough (RCC) signifies a strategic development as the company prepares for the next phases of its project.

Key Takeaways:

• Trevi Therapeutics is progressing in the development of treatments for chronic cough and IPF.
• The RIVER trial for RCC is currently 80% enrolled, with data expected in Q4 2024.
• Enrollment is ongoing for the CORAL Phase 2b trial for IPF chronic cough, with topline data anticipated in the first half of 2025.
• Additional supportive studies, including a human abuse potential (HAP) research, are in progress.
• The reported net loss of $12.4 million for Q2 2024 included R&D expenses totaling $10 million.
• Trevi expects a cash runway extending into 2026.

Company Outlook:

• Trevi is optimistic about its Phase 2a trial in IPF chronic cough and is preparing for future trials, conducting supportive studies to enhance its research efforts.
• The company is particularly focused on developing Haduvio and is considering its market positioning in light of upcoming trial results.

Bearish Highlights:

• Trevi reported an increase in net loss compared to the same period last year, rising from $7.1 million in Q2 2023 to $12.4 million in Q2 2024.

Bullish Highlights:

• The CORAL and RIVER trials are progressing well, showing positive enrollment trends.
• The company has substantial patent coverage for its products, potentially securing it through 2043.

Clinical Updates:

• The RIVER trial for RCC has approximately 80% of participants enrolled, aiming to conclude by year-end.
• The CORAL trial for IPF chronic cough involves around 160 patients, with data analysis expected soon.
• Trevi has also initiated a Phase 1 study to evaluate respiratory physiology in IPF patients.

Throughout the call, Trevi’s leadership reiterated its commitment to addressing the significant unmet needs in chronic cough and IPF, highlighting the company’s vigorous planning and robust patent protection as a strong basis for future growth. With multiple data readouts on the horizon, Trevi Therapeutics is positioning itself as a noteworthy entity in the biopharmaceutical landscape.